MindMed doses first patient in Phase 3 Voyage study of MM120 for GAD

Definium Therapeutics, Inc.

First-ever Phase 3 study of lysergide D-tartrate (LSD) for GAD; primary endpoint HAM-A change at week 12 vs placebo.
Voyage study to enroll ~200 participants in US; topline data from 12-week double-blind period expected H1 2026.
Builds on positive Phase 2b study results presented at APA Annual Meeting in May 2024; second Phase 3 Panorama study on track for H1 2025.
MM120 ODT is a pharmaceutically optimized form of LSD; study includes 52-week duration with 40-week open-label extension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.